Profilaxis secundaria con rFVIIIFc en adultos jóvenes con hemofilia A severa
Revista Hematología ENERO - ABRIL 2020
pdf

Palabras clave

profilaxis, hemofilia, rFVIIIFc, adultos jóvenes, tasa de sangrado.

Cómo citar

Elhelou, L., Neme, D., Cocca, A., & Primiani, L. (2020). Profilaxis secundaria con rFVIIIFc en adultos jóvenes con hemofilia A severa. Revista Hematología, 24(1), 49–53. Recuperado a partir de http://revistahematologia.com.ar/index.php/Revista/article/view/223

Resumen

Introduction: Secondary prophylaxis in adults with severe haemophilia will not resolve the established arthropathy but may reduce the number of joint bleeds. Extend ed half-life products permit less frequent infusions.
Aim: In this prospective study, we evaluated the efficacy of prophylaxis with recombinant FVIII Fc fusion
protein (rFVIIIFc) in a group of young adult patients.
Methods: Patients older than 18 years old from a single center were treated with rFVIIIFc 20-40 IU kg-1 twice a week, during a period of 6 months. We analyzed the annualized bleeding rate and compared it with the pre-prophylaxis period (on demand treatment).
Results: 24 patients received a mean dose of rFVIIIFc 32.1 kg-1 twice a week. There were 58 minor bleedings,
all treated with 1-2 daily dose of rFVIIIFc. The mean annualized bleeding rate was 15.3 in the pre-prophylaxis period vs. 2.4 during prophylaxis. No inhibitors were detected.
Conclusion: rFVIIIFc was well-tolerated in young adult patients with severe hemophilia A, and resulted in low bleeding rate when dosed 2 times per week as a secondary prophylactic treatment.

pdf

Citas

1. Hay C. Prophylaxis in adults with haemophilia. Haemophilia. 2007; 13 (Suppl. 2): 10-15.
2. Nolan B, Mahlangu J, Perry D y col. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016; 22: 72-80.
3. Sommer J, Moore N, McGuffie-Valentine B y col. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia. 2014; 20: 294-300.
4. Mahlangu J, Powell J, Ragni M y col. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014; 123 (3): 317-325.
5. Berntorp E, Negrier C, Gozzi P y col. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. Haemophilia. 2016; 22: 389-396.
6. Fischer K, van Dijk K, van den Berg M. Results of prophylaxis started in adulthood. Haemophilia. 2006;10: 113-16.
7. Noone D, O’Mahony B, Prihodova L. A survey of the outcome of prophylaxis, on-demand or combined treatment in 20–35 year old men with severe haemophilia in four European countries. Haemophilia. 2011;17: e842-3.
8. Berntorp E, Dolan G, Hay C y col. European retrospective study of real-life haemophilia treatment. Haemophilia. 2017; 23: 105-114.
9. Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia .2003; 9 (Suppl. 1): 101-10.
10. Fischer K, van der Bom JG, Molho P et al. Prophylactic vs. on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia. 2002; 8: 745-52.
11. Coppola A, D'Ausilio A, Aiello A y col; Potter Study Group. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. Haemophilia. 2017; 23:422-429.
12. Iorio A, Krishnan S, Mirén K y col. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products. Haemophilia. 2017; 23:408-416.
13. Makris M. Prophylaxis in haemophilia should be lifelong. Blood Transfus. 2012; 10 (2): 165-168.

Todo el material publicado en la revista Hematología (versión electrónica y versión impresa), será cedido a la Sociedad Argentina de Hematología. De conformidad con la ley de derecho de autor (ley 11723) se les enviara a los autores de cada trabajo aceptado formulario de cesión de derechos de autor que deberá ser firmado por todos los autores antes de la publicación. Los autores deberán retener una copia del original pues la revista, no acepta responsabilidad por daños o pérdidas del material enviado. Los autores deberán remitir una versión electrónica al correo: revista@sah.org.ar

Descargas

Los datos de descargas todavía no están disponibles.